Preprint RCT in healthy adults suggests multi-target supplement may improve endothelial function and arterial stiffness.
The longevity sector has spent the better part of a decade promising a pivot toward clinical rigor; in practice, that shift has been uneven – occasionally convincing, but more often aspirational. Now, NOVOS has released preprint data from a randomized, double-blind, placebo-controlled trial examining the effects of a multi-component nutritional intervention on vascular aging in adults aged 40 and over. The results are early, certainly, but they are also structured – offering measurable changes across several established markers of cardiovascular function rather than the usual vague promises of “vitality.”
Funded by NOVOS (though the company had no role in data collection or primary analysis) and conducted at the University of Surrey and led by Professor Christian Heiss, the study enrolled 61 apparently healthy participants, with 43 completing the six-month protocol. The primary endpoint was flow-mediated dilation (FMD) – a sensitive, functional measure of how well the endothelium actually responds to stress – while secondary endpoints tracked carotid-femoral pulse wave velocity (PWV) and systolic blood pressure. Across the board, the intervention group demonstrated improvements relative to placebo that the authors describe not just as statistical noise, but as a coherent shift in the underlying biology of vascular aging [1].
Longevity.Technology: Longevity interventions aimed at prevention are increasingly sitting on a fault line – between the wellness world, which has rarely met a sweeping claim it did not enjoy, and the clinical world, which tends to ask for replication, peer review and a little less enthusiasm. That is precisely what makes data like these interesting. A randomized, double-blind, placebo-controlled trial in healthy adults over 40 showing improvements in flow-mediated dilation, pulse wave velocity and systolic blood pressure is not nothing; in a supplements category more accustomed to metabolic mood music than properly specified vascular endpoints, it marks a notable change of tone. At the same time, a preprint remains a preprint – small, single-center and built around surrogate markers rather than hard outcomes, however relevant those markers may be to cardiovascular aging. The more interesting question, perhaps, is whether this is what the supplement space looks like when it starts to grow up: less breathless promise, more measured biology; less antiaging pantomime, more data that can at least survive contact with scrutiny. If longevity is serious about prevention – and it should be – then interventions aimed at apparently healthy midlife adults will need exactly this sort of scientific scaffolding, even if the scaffolding is not yet the building. The challenge now is not merely to post encouraging numbers, but to show that they endure, replicate and translate.
A study in vascular function
At the six-month mark, the data began to show some teeth: endothelial function improved by 2.9% in the intervention group relative to placebo. Arterial stiffness – measured via the gold-standard carotid–femoral pulse wave velocity – fell by 1.18 m/s, while systolic blood pressure dropped by a notable 6.1 mmHg [1].
Individually, these shifts sit within a range considered clinically meaningful in vascular research; for context, the improvements in flow-mediated dilation (FMD) and pulse wave velocity (PWV) reported here actually exceed those typically seen in studies of resistance training or high-intensity interval training. Together, they begin to sketch a logical pattern rather than an isolated fluke. Endothelial function reflects the “software” of the system – nitric oxide signaling and vascular reactivity – while pulse wave velocity captures the “hardware” or structural stiffness along the arterial tree. Blood pressure essentially integrates both, expressing the entire system under load. That all three markers moved in the same direction lends the findings a certain internal consistency – it’s not definitive proof of a reversed aging trajectory, but it is a signal with enough resonance to be worth noting.
As senior author Dr Christian Heiss, Professor of Cardiovascular Medicine at the University of Surrey, puts it, “Taken together, improvements across endothelial function, arterial flexibility, and systolic blood pressure point to a coherent pattern consistent with a favorable shift in vascular aging biology.”
Lipid profiles, meanwhile, remained unchanged – a detail that matters [1]. The effect, such as it is, appears to operate through endothelial and hemodynamic pathways rather than lipid modulation, a reminder that cardiovascular risk is not a single axis but a network.
Targeting systems, not single pathways
The formulation itself is unapologetically plural. Rather than isolating one compound, it combines multiple bioactives intended to act across oxidative stress, mitochondrial function, inflammation and nitric oxide signaling – a design philosophy drawn directly from the hallmarks of aging framework.
There is a certain coherence to this approach; vascular aging is not driven by one pathway, so why intervene as if it were? At the same time, it complicates interpretation. Twelve components, each with plausible mechanisms (including alpha-ketoglutarate, fisetin, pterostilbene), make attribution difficult. The biology may be systemic; the evidence, necessarily, is not yet that granular.
Prevention in practice
More interesting, perhaps, is who was studied. Not patients, not high-risk cohorts, but generally healthy adults in midlife – individuals in whom vascular decline is underway but not yet clinically expressed [1]. This is where prevention lives, in theory; it is also where signal detection becomes more difficult.
Small changes. Early shifts.
In that context, even modest movements in validated biomarkers begin to carry weight. Epidemiological data suggest that relatively small reductions in systolic blood pressure are associated with meaningful differences in cardiovascular risk; endothelial function, while more indirect, carries similar predictive associations.
Heiss frames it more directly: “This trial provides rare human evidence that a multi-pathway nutritional strategy can meaningfully influence cardiovascular aging biology itself. The magnitude and consistency of these effects across multiple cardiovascular endpoints is unusual for a nutritional intervention in a healthy population.”
Interpreting early signals
Still, caution has its place. This is a single-center study with a modest sample size; attrition reduced the number of participants included in the final analysis. The endpoints, while well established, are surrogate measures – informative, but not definitive. And, as a preprint, the work has yet to pass through peer review.
None of which invalidates the findings. It simply situates them – early, structured, incomplete.
Between categories
There is, running through all of this, a quieter shift. Nutritional interventions – long positioned somewhere between lifestyle advice and commercial wellness – are beginning, at least in places, to adopt the methodological language of clinical science. Randomization. Blinding. Defined endpoints.
It changes the conversation. Not entirely, not yet – but enough to notice.
Where the signal leads
If longevity is serious about moving upstream, then interventions will need to show not just that they can nudge biomarkers over months, but that they can alter trajectories over years. That kind of evidence accumulates slowly.
For now, the direction is clearer than the destination.
Photograph courtesy of NOVOS
